Clinical stage pharmaceutical development Company
Algernon Pharmaceuticals Inc. (
CSE: AGN,
OTCQB: BTHCF,
Forum) stated Monday that one of its lead compounds for non-alcoholic steatohepatitis - NP-135 - demonstrated a 34.6 per-cent reduction of a key secondary marker of fibrosis, liver hydroxyproline. This is in addition to being metabolically neutral in a number of important measurements.
For more,
click here.
The Company recently announced that leading global expert and clinician in the area of chronic liver disease, Dr. Arun Sanyal, has joined its Medical and Scientific Advisory Board.
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.